Mitoxantrone encapsulated nanocells - EnGeneIC

Drug Profile

Mitoxantrone encapsulated nanocells - EnGeneIC

Alternative Names: EGFREDVMitoxantrone; EEDVSMit; EGFR-ErbituxEDVsMIT; Kid EDV; Mitoxantrone packaged EDV™ nanocells - EnGeneIC; Mitoxantrone packaged EnGeneIC Delivery Vehicle; Mitoxantrone packaged EnGeneIC Dream Vector

Latest Information Update: 15 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EnGeneIC
  • Class Anthraquinones; Antineoplastics; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I CNS cancer; Solid tumours

Most Recent Events

  • 28 Jan 2016 Engeneic plans the phase I ECREST trial for Solid tumours and CNS cancer (Second-line therapy or greater, Recurrent, In children, In adolescents) in Australia (IV, injection) (NCT02687386)
  • 27 Jan 2016 Preclinical trials in CNS cancer and Solid tumours in Australia (IV) before January 2016
  • 07 Oct 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top